SEARCH

SEARCH BY CITATION

References

  • 1
    Thompson D. Understanding financial conflicts of interest. N Engl J Med 1993; 329: 5736.
  • 2
    Rothman KJ. Conflict of interest: the New McCarthyism in science. JAMA 1993; 269: 27824.
  • 3
    Borgert CJ. Conflict of interest or contravention of science? Regul Toxicol Pharmacol 2007; 48: 45.
  • 4
    Tagore A. Drug promotion tactics – yet another pharma deception. Int J Clin Pract 2014; 68: 6625.
  • 5
    Kuran T, Sunstein C. Availability cascades and risk regulation. Stanford Law Rev 1999; 51: 683768.
  • 6
    Lesko R, Scott S, Stossel T. Bias in high-tier medical journals concerning physician-academic relations with industry. Nat Biotechnol 2012; 30: 3202.
  • 7
    Spurling GK, Mansfield PR, Montgomery BD et al. Information from pharmaceutical companies and the quality, quantity, and cost of physicians’ prescribing: a systematic review. Plos Med 2010; 7: e1000352.
  • 8
    Chressanthis G, Khedkar P, Jain N et al. Can access limits on sales representatives to physicians affect clinical prescription decisions? A study of recent events with diabetes and lipid drugs. J Clin Hypertens 2012; 14: 43546.
  • 9
    Lichtenberg FR. Are the benefits of newer drugs worth their cost? Evidence from the 1996 MEPs. The newer the drug in use, the less spending on nondrug items Health Aff 2001; 20: 24151.
  • 10
    Lichtenberg FR. On “New Cardiovascular Drugs: Patterns of Use and Association with Non-Drug Health Expenditures”. Inquiry 2006; 43: 804.
  • 11
    Lichtenberg FR. The impact of new drugs on US longevity and medical expenditure, 1990-2003: evidence from longitudinal, disease-level data. Am Econ Rev 2007; 97: 43844.
  • 12
    Lichtenberg FR. Effects of new drugs on overall health spending: Frank Lichtenberg responds. Health Aff 2007; 26: 88790.
  • 13
    Civan A, Köksal B. The effect of newer drugs on health spending: do they really increase the costs? Health Econ 2010; 19: 58195.
  • 14
    Santerre RE. National and international tests of the new drug cost offset theory. South Econ J 2011; 77: 103343.
  • 15
    Lichtenberg FR; Manhattan Institute for Policy Research. Alive and working: how access to new drugs has slowed the growth in America's disability rates, 2008. Report no. 7.
  • 16
    Lichtenberg FR. The impact of new drug launches on longevity: evidence from longitudinal, disease-level data from 52 countries, 1982-2001. Int J Health Care Finance Econ 2005; 5: 4773.
  • 17
    Lichtenberg FR. The effect of pharmaceutical innovation on the functional limitations of elderly Americans: evidence from the 2004 National Nursing Home Survey. Adv Health Econ Health Serv Res 2012; 23: 73101.
  • 18
    Lichtenberg FR. Contribution of pharmaceutical innovation to longevity growth in Germany and France, 2001-7. Pharmacoeconomics 2012; 30: 197211.
  • 19
    DiMasi JA, Faden LB. Competitiveness in follow-on drug R&D: a race or imitation? Nat Rev Drug Discov 2011; 10: 237.
  • 20
    Moynihan R, Heath I, Henry D. Selling sickness: the pharmaceutical industry and disease mongering. BMJ 2002; 324: 88891.
  • 21
    Moynihan R, Cassells A. Selling Sickness. How the World's Biggest Pharmaceutical Companies are Turning Us All into Patients. New York, NY: Nation Books, 2006.
  • 22
    Greenberg GJ. Manufacturing Depression: The Secret History of a Modern Disease. 1st Simon & Schuster hardcover edn. New York, NY: Simon & Schuster, 2010.
  • 23
    LaMattina J. Drug Truths. Dispelling the Myths about Pharma R&D. Hoboken, NJ: Wiley, 2009.
  • 24
    Goldberg R. Tabloid Medicine. How the Internet is Being Used to Hijack Medical Science for Fear and Profit. New York, NY: Kaplan Publishing, 2010.
  • 25
    Lasser K, Allen P, Woolhandler S et al. Timing of new black box warings and withdrawals for prescription medications. JAMA 2002; 287: 221520.
  • 26
    Brody H. The company we keep: why physicians should refuse to see pharmaceutical representatives. Ann Fam Med 2005; 3: 825.
  • 27
    Fugh-Berman A, Ahari S. Following the script: how drug reps make friends and influence doctors. PLoS Med 2007; 4: e150. doi:10.1371/journal.
  • 28
    Korenstein D, Keyhani S, Ross J. Physician attitudes toward industry. A view across the specialties. Arch Surg 2010; 145: 5707.
  • 29
    Dana J, Loewenstein G. A social science perspective on gifts to physicians from industry. JAMA 2003; 290: 2525.
  • 30
    PhRMA. Code on Interactions with Healthcare Professionals. Washington, DC: Pharmaceutical Researchers and Manufacturers of America, 2008.
  • 31
    ADVAMED. Code of Ethics on Interactions with Health Care Professionals. Washington, DC: Advanced Medical Technology Association, 2008.
  • 32
    von Mises L. Human Action. A Treatise on Economics. Irvington on Hudson, NY: The Foundation for Economic Education Inc, 1963.
  • 33
    Kravitz R, Epstein R, Feldman M et al. Influence of patients’ requests for direct-to-consumer advertised antidepressants: a randomized controlled trial. JAMA 2005; 293: 19952002.
  • 34
    ACCME. ACCME 2012 annual report, 2012.
  • 35
    Accreditation Council for Contuing Medical Education (ACCME). Standards for commercial support. Standards to ensure the independence of CME activities, 2004 September.
  • 36
    Kawczak S, Carey W, Lopez R, Jackman D. The effect of industry support on participants’ perception of bias in continuing medical education. Acad Med 2010; 85: 804.
  • 37
    Steinman MA, Boscardin CK, Aguayo L, Baron RB. Commercial influence and learner-perceived bias in continuing medical education. Acad Med 2010; 85: 749.
  • 38
    Ellison J, Hennekens C, Wang J et al. Low rates of reporting commercial bias by physicians following online continuing medical education activities. Am J Med 2009; 122: 8758.
  • 39
    Lexchin J, Cassels A. Does the C in CME stand for “Continuing” or “Commercial”? Can Med Assoc J 2005; 172: 1602.
  • 40
    Mueller P, Hook C, Litin S. Physician preferences and attitudes regarding industry support of CME. Am J Med 2007; 120: 2815.
  • 41
    Levy MM, Dellinger RP, Townsend SR et al. The surviving sepsis campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Crit Care Med 2010; 38: 36774.
  • 42
    Silverglate H. Three Felonies a Day. How the Feds Target the Innocent. New York/London: Encounter Books, 2009.
  • 43
    Wilson D. Novartis settles off-lable marketing case over 6 drugs for $422.5 Million. The New York Times, 2010.
  • 44
    Ross J, Hill K, Egilman D, Krumholz H. Guest authorship and ghostwriting in publications related to Rofecoxib. A case study of industry documents from Rofecoxib litigation. JAMA 2008; 299: 180012.
  • 45
    Woolley KL, Lew RA, Ely JA et al. Lack of medical writers and the pharmaceutical industry in publications retracted for misconduct: a systematic, controlled, retrospective study. Curr Med Res Opin 2011; 27: 117582.
  • 46
    Lundh A, Sismondo S, Lexchin J et al. Industry sponsorship and research outcome. Cochrane Database Syst Rev 2012; 12: MR000033-MR.
  • 47
    Khan NA, Lombeida JI, Singh M et al. Association of industry funding with the outcome and quality of randomized controlled trials of drug therapy for rheumatoid arthritis. Arthritis Rheum 2012; 64: 205967.
  • 48
    Del Parigi A. Industry funded clinical trials: bias and quality. Curr Med Res Opin 2012; 28: 235.
  • 49
    Kahneman D. Thinking Fast and Slow: Farrar. New York, NY: Straus and Giroux, 2011.
  • 50
    Stelfox HT, Chua G, O'Rourke K, Detsky AS. Conflict of interest in the debate over calcium – channel antagonists. N Engl J Med 1998; 338: 1016.
  • 51
    Zinner D, Bjankovic B, Clarridge B et al. Participation of academic scientists in relationships with industry. Health Aff 2009; 28: 181425.
  • 52
    Wright JM, Musini VM. First-line drugs for hypertension. Cochrane Database Syst Rev 2009: CD001841.
  • 53
    Tufts Center for the Study of Drug Development. Large pharma success rate for drugs entering clinical trials in 1993–2004: 16%. Impact Report, 2009.
  • 54
    Hay M, Thomas DW, Craighead JL et al. Clinical development success rates for investigational drugs. Nat Biotechnol 2014; 32: 4051.
  • 55
    DiMasi J, Grabowski H. The cost of biopharmaceutical R&D: is biotech different? Managerial Decision Econ 2007; 28: 46979.
  • 56
    Stossel TP. Regulating academic-industrial research relationships — solving problems or stifling progress? N Engl J Med 2005; 353: 10605.
  • 57
    Stell L. Against the flow: why physicians should listen to drug reps. ASBH Exchange 2005; 8: 15.
  • 58
    Glazer W. Rebuttal: questioning the validity of ‘anatomy of an epidemic’ (part 1). Behav Healthcare 2011; 31: 425.
  • 59
    Glazer W. Rebuttal: questioning the validity of ‘anatomy of an epidemic’ (part II). Behav Healthcare 2011; 31: 427.